<em><strong>Bacteroides vulgatus</strong></em><strong> alleviates non-alcoholic fatty liver disease progression by downregulating histone acetylation level via 3-HPAA</strong> Untitled Item

Non-alcoholic fatty liver disease (NAFLD) is a prevalent metabolic disease that lacks effective interventions. Gut microbiota-based therapy may provide a new strategy for addressing this problem. In this study, we discovered <em>Bacteroides vulgatus (B. vulgatus) </em>as a potential probiotic of NAFLD using multi-omics analysis. Results of murine models display the supplementation of <em>B. vulgatus</em> alleviates the development of NAFLD. The mechanism underlying this effect is attributed to the metabolite 3-Hydroxyphenylacetic acid (3-HPAA) produced by <em>B. vulgatus</em>, which reduces the acetylation levels of H3K27 and downregulates the transcription of <em>Squalene Epoxidase (SQLE)</em>, a rate-limiting enzyme in steroid biosynthesis to promote lipid accumulation, in liver cells. This study highlights the significant role of <em>B. vulgatus</em> in NAFLD development and the critical role of its metabolite 3-HPAA, which is involved in lipid homeostasis. It offers a potential solution for early intervention therapy for NAFLD.